September 22, 2021

Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021

Multiple presentations to showcase data from lead clinical program for the treatment of the leading cause of complications in patients undergoing joint replacement surgery

PITTSBURGH, PA, September 22, 2021 –  Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life threatening diseases, will present first-in-human Phase 1 data on its lead investigational therapy PLG0206 for the treatment of prosthetic joint infection (PJI) at IDWeek 2021 taking place September 29 through October 3.

PLG0206 is a best-in-class, broad-spectrum anti-infective, which has potent activity against biofilm. PLG0206 has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for the treatment of PJI, which can result following a joint replacement procedure. PLG0206 has a unique mechanism of action that works by targeting and disrupting bacterial membranes leading to the rapid killing of bacterial cells. Using unique peptide engineering techniques, Peptilogics has optimized PLG0206 both for safety and broad-spectrum activity against biofilms produced by bacteria that harbor and protect bacteria from most antibiotics.

More than one million total joint replacements are performed annually in the U.S., a number that is expected to grow to 4 million annual procedures by 2030 due to an aging and growing population. Following joint replacement, 1-2% of patients will develop a PJI, a serious, life-threatening condition which often necessitates a major surgical procedure to resolve the infection. These additional follow-on surgeries carry a 60% failure rate and result in substantial numbers of patient deaths, evidenced by a 25% 5-year mortality rate.

Peptilogics will present data from three accepted abstracts including its first-in-human Phase 1 clinical safety data, results from a PJI patient explant study, and in vitro activity against bacteria commonly found in PJIs.

·      A Phase 1 safety and tolerability of single ascending doses of a novel engineered Cationic Peptide, PLG0206, in healthy subjects (Poster #1070720)

·     Knee explant analysis (KnEA) using PLG0206 in periprosthetic joint infection (KnEA Study) (Poster #1070556)

·     In vitro activity of PLG0206 against isolates commonly found in periprosthetic joint infections(Poster #1070530)

IDWeek presentations will be available to conference attendees on-demand beginning Sept. 29 through ID Week’s Interactive Program.

About Peptilogics
Peptilogics engineers peptide therapeutics to radically improve the treatment landscape for patients with life-threatening diseases. Through biological and pharmaceutical expertise, novel artificial intelligence algorithms, and purpose-built super-computing, Peptilogics is advancing an extensive therapeutic pipeline and accelerating discovery efforts at a pace and scale that was previously impossible. Peptilogics is backed by visionary investors in life science and technology including Thiel Capital, Presight Capital, CARB-X, and Founders Fund. For more information about Peptilogics, visit or follow the company on Twitter and LinkedIn.

This research is supported by Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). CARB-X funding for this research is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and by an award from the Wellcome Trust. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the HHS Office of the Assistant Secretary for Preparedness and Response, or other CARB-X funders.

Media Contact:
Liz Boten

Peptilogics Contact:
Jodie Gillon
SVP Corporate Affairs & Patient Advocacy